Skip to main content
Log in

Metastatic Soft Tissue Sarcoma in Adults

Prognosis and Treatment Options

  • Review Article
  • Published:
American Journal of Cancer

Abstract

In the present paper the treatment of advanced and metastatic soft tissue sarcoma is reviewed with the primary emphasis on chemotherapy. One of the major advances in the treatment of soft tissue sarcomas is their treatment by multidisciplinary teams in specialized centers. Despite optimal local treatment of the primary tumor, disseminated disease will develop in many patients. Consequently, chemotherapy has been extensively studied but, unfortunately, the responsiveness of these tumors to chemotherapy has been disappointingly low. Doxorubicin and ifosfamide appear to be the most effective drugs — the latter with a somewhat higher toxicity at effective dosages. Other drugs with some first line activity are dacarbazine, liposomal doxorubicin and possibly trabectedin (ET-743). Imatinib is very effective in gastrointestinal stromal tumors (GIST) where it is now the treatment of choice. The combination of doxorubicin and ifosfamide increases the response rate without affecting overall survival. For these reasons, single agent doxorubicin is, in many centers, considered the standard treatment for advanced soft tissue sarcoma, and combination chemotherapy should be reserved for special subgroups of patients such as young patients with chemosensitive tumors. Chemotherapy for patients with advanced and metastatic soft tissue sarcoma is inadequate at present and new drugs are desperately needed. Fortunately, exciting new drugs are under development and hopefully they will improve the treatment of patients with this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Fig. 2

Similar content being viewed by others

References

  1. Brennan MF, Alektiar KM, Maki RG. Soft tissue sarcoma. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer principles & practice of oncology. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 1841–90

    Google Scholar 

  2. Dirix LY, van Oosterom AT. Soft tissue sarcoma in adults. Curr Opin Oncol 1999; 11: 285–95

    Article  PubMed  CAS  Google Scholar 

  3. Storm HH. Survival of adult patients with cancer of soft tissues or bone in Europe. Eur J Cancer 1998; 34: 2212–7

    Article  PubMed  CAS  Google Scholar 

  4. Flugstad DL, Wilke CP, McNutt MA,. Importance of surgical resection in the successful management of soft tissue sarcoma. Arch Surg 1999; 134: 856–61

    Article  PubMed  CAS  Google Scholar 

  5. Siebenrock KA, Hertel R, Ganz R. Unexpected resection of soft-tissue sarcoma. More mutilating surgery, higher local recurrence rates, and obscure prognosis as consequences of improper surgery. Arch Orthop Trauma Surg 2000; 120: 65–9

    PubMed  CAS  Google Scholar 

  6. O’Sullivan B, Wylie J, Catton C, et al. The local management of soft tissue sarcoma. Semin Radiat Oncol 1999; 9: 328–48

    Article  PubMed  Google Scholar 

  7. Lewis JJ, Leung D, Espat J, et al. Effect of re-resection in extremity soft tissue sarcoma. Ann Surg 2000; 231: 655–63

    Article  PubMed  CAS  Google Scholar 

  8. O’Byrne K, Steward WP. The role of chemotherapy in the treatment of adult soft tissue sarcomas. Oncology 1999; 56: 13–23

    Article  PubMed  Google Scholar 

  9. Verweij J, Mouridsen HT, Nielsen OS, et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Crit Rev Oncol Hematol 1995, 201

  10. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997; 350: 1647–54

    Article  Google Scholar 

  11. Adjuvant chemotherapy for localized resectable soft tissue sarcoma in adults. Available in the Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 4. Oxford: Update Software, 2000: CD001419

  12. Nielsen OS, Dombernowsky P, Mouridsen H, et al. Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue sarcomas: the experience of the EORTC soft tissue and bone sarcoma group. Sarcoma 2000; 4: 31–5

    Article  PubMed  CAS  Google Scholar 

  13. van Geel AN, Pastorino U, Jauch KW, et al. Surgical treatment of lung metastases: the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer 1996; 77: 675–82

    Article  PubMed  Google Scholar 

  14. Pastorino U. Metastasectomy for soft tissue sarcomas. Cancer Treat Res 1997; 91: 65–75

    Article  PubMed  CAS  Google Scholar 

  15. Launchbury AP, Habboubit N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993; 19: 197–228

    Article  PubMed  CAS  Google Scholar 

  16. Bramwell VHC, Mouridsen HT, Mulder JH, et al. Carminomycin vs. adriamycin in advanced soft tissue sarcomas: an EORTC randomized phase II study. Eur J Cancer Clin Oncol 1983; 19: 1097–104

    Article  PubMed  CAS  Google Scholar 

  17. Bull FE, von Hoff DD, Balcerak SP, et al. Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study. Cancer Treat Rep 1985; 69: 231–3

    PubMed  CAS  Google Scholar 

  18. Mouridsen HT, Bastholt L, Somers R, et al. Adria-mycin versus epirubicin in advanced soft tissue sarcomas: a randomized phase II/phase III study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer Clin Oncol 1987; 23: 1477–83

    Article  PubMed  CAS  Google Scholar 

  19. Nielsen OS, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas: a study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 1998; 78: 1634–9

    Article  PubMed  CAS  Google Scholar 

  20. Toma S, Tucci A, Villani G, et al. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). Anticancer Res 2000; 20(1B): 485–91

    PubMed  CAS  Google Scholar 

  21. Judson I, Radford JA, Harris M, et al. Randomized phase II trial of pegylated liposomal doxorubicin (Doxil®/Caelyx®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001; 37: 870–7

    Article  PubMed  CAS  Google Scholar 

  22. Hoefer-Janker H, Scheef U, Gunther U, et al. Erfahrungen mit der franctionierten ifosfamide-stosstherapie bei generalisierten malignant tumoren. Med Welt 1975; 26: 972–9

    PubMed  CAS  Google Scholar 

  23. Bruhl P, Gunther U, Hoefer-Janker H, et al. Results obtained with fractionated ifosfamide massive dose treatment in generalized malignant tumors. Int J Clin Pharmacol 1976, 39

  24. Zalupski M, Baker LH. Ifosfamide. J Natl Cancer Inst 1988; 80: 556–66

    Article  PubMed  CAS  Google Scholar 

  25. Dirix LY, van Oosterom AT. The role of if osfamide in the treatment of adult soft tissue sarcomas, Ewing’s sarcoma, and osteosarcoma: a review. Sem Oncol 1990; 17Suppl. 4: 55–7

    Google Scholar 

  26. Stuart-Harris RC, Harper PG, Parsons CA, et al. High dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced softtissue sarcoma. Cancer Chemother Pharmacol 1983; 11: 69–72

    Article  PubMed  CAS  Google Scholar 

  27. Bramwell VHC, Mouridsen HT, Santoro A, et al. Cyclophosphamide vs ifosfamide: a randomized phase II trial in adult soft tissue and bone sarcoma. Preliminary report of EORTC Soft Tissue and Bone Sarcoma Group [abstract]. Proc Am Soc Clin Oncol 1985; 4: 143

    Google Scholar 

  28. Antman KH, Ryan L, Elias A, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989; 1: 126–31

    Google Scholar 

  29. van Oosterom AT, Krzemienlecki K, Nielsen OS, et al. Randomized phase II study of the EORTC Soft Tissue and Bone Sarcoma Group comparing two different ifosfamide regimens in chemotherapy untreated advanced soft tissue sarcoma patients. Eur J Cancer. In press.

  30. Nielsen OS, Judson I, van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas: a multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2000; 36: 61–7

    Article  PubMed  CAS  Google Scholar 

  31. Le Cesne A, Antoine E, Spielman M, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600–8

    PubMed  Google Scholar 

  32. Patel SR, Vadham-Raj S, Papadopolous N, et al. High-dose ifosfamide in body and soft tissue sarcomas: results of phase II and pilot studies: dose response and schedule dependence. J Clin Oncol 1997; 15: 2378–84

    PubMed  CAS  Google Scholar 

  33. Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients — preliminary evidence of activity. J Clin Oncol 2001; 19: 1248–55

    PubMed  CAS  Google Scholar 

  34. Demetri GD, Seiden M, Garcia-Carbonero R, et al. ET743 shows promising activity in distinct populations of sarcoma patients: summary of 3 phase II trials [abstract]. Proc Am Soc Clin Oncol 2000; 19: 553a (2177)

    Google Scholar 

  35. Le Cesne A. Phase II study of ET743 in advanced soft tissue sarcomas (ASTS) in adults. A STBSG EORTC Trial [abstract]. Proc Am Soc Clin Oncol 2000; 19: 554a (2182)

    Google Scholar 

  36. Amodio A, Carpano S, Manfredi C, et al. Gemcitabine in advanced soft tissue sarcoma: a phase II study. Clin Ter 1999; 150: 17–20

    PubMed  CAS  Google Scholar 

  37. Svancarova L, Blay JY, Judson IR, et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38(4): 556–9

    Article  PubMed  CAS  Google Scholar 

  38. Kollmannsberger C, Brugger W, Hartmann JT, et al. Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs 1999; 10: 453–6

    Article  PubMed  CAS  Google Scholar 

  39. Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 2000; 18(10): 2081–6

    PubMed  CAS  Google Scholar 

  40. Sutton G, Blessing JA, Ball H. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 1999; 74: 346–9

    Article  PubMed  CAS  Google Scholar 

  41. Fata F, O’Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999; 86: 2034–7

    Article  PubMed  CAS  Google Scholar 

  42. Patel S, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998; 21: 317–21

    Article  PubMed  CAS  Google Scholar 

  43. Reichardt P, Tilgner J, Hohenberger P, et al. Dose-intensive chemotherapy with ifosfamide, epirubicin and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998; 16: 1438–43

    PubMed  CAS  Google Scholar 

  44. Leyvraz S, Bacchi M, Cerny T, et al. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas, Swiss Group for Clinical Research (SAKK). Ann Oncol 1998; 9: 877–84

    Article  PubMed  CAS  Google Scholar 

  45. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CyVADIC versus ifosfamide plus doxorubicin in first line treatment of advanced soft tissue sarcomas: a randomized study of the EORTC Soft tissue and bone sarcoma group. J Clin Oncol 1995; 13: 1537–45

    PubMed  CAS  Google Scholar 

  46. Steward WP, Verweij J, Somers R, et al. Granulocyte-macrophage colonystimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993; 11(1): 15–21

    PubMed  CAS  Google Scholar 

  47. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colonystimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000; 18(14): 2676–84

    PubMed  Google Scholar 

  48. Schoenfeld DA, Rosenbaum C, Horton J, et al. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 1982; 50(12): 2757–62

    Article  PubMed  CAS  Google Scholar 

  49. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5(6): 840–50

    PubMed  CAS  Google Scholar 

  50. Edmonson JH, Ryan LM, Blum RG, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cis-platin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269–75

    PubMed  CAS  Google Scholar 

  51. O’Bryan RM, Baker LH, Gottlieb JB, et al. Dose response evaluation of adriamycin in neoplasm. Cancer 1977; 39: 1940–8

    Article  PubMed  Google Scholar 

  52. Elias AD, Eder JP, Skea T, et al. High dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol 1990; 8: 170–8

    PubMed  CAS  Google Scholar 

  53. Cerny T, Leyvraz S, Daggi H, et al. Phase II trials of ifosfamide and mesna in advanced soft tissue sarcoma patients: a definite dose-response relationship [abstract]. Proc Am Soc Clin Oncol 1992; 11: 416

    Google Scholar 

  54. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 1994; 73: 2506–11

    Article  PubMed  CAS  Google Scholar 

  55. Saeter G, Alvegaard TA, Monge OR, et al. Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma: a Scandinavian Sarcoma Group Phase II Study. Eur J Cancer 1997; 33: 1551–8

    Article  PubMed  CAS  Google Scholar 

  56. Jelic S, Kovcin V, Milanovic N, et al. Randomized study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer 1997; 33: 220–5

    Article  PubMed  CAS  Google Scholar 

  57. Antman KH, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide an Mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11: 1276–85

    PubMed  CAS  Google Scholar 

  58. Horowitz ME, Kinsella TJ, Wexler LH, et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing’s sarcoma and rhabdomyosarcoma. J Clin Oncol 1993; 11: 1911–8

    PubMed  CAS  Google Scholar 

  59. Koscielniak E, Klingebiel TH, Peters C, et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue?. Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 1997; 19: 227–31

    Article  PubMed  CAS  Google Scholar 

  60. Burdach S, Jurgens H, Peters C, et al. Myeloablative radiochemotherapy and hematopoietic stem cell rescue in poor-prognosis Ewing’s sarcoma. J Clin Oncol 1993; 11: 1482–8

    PubMed  CAS  Google Scholar 

  61. Boulad F, Kernan NA, LaQuaglia MP, et al. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing’s sarcoma, and undifferentiated sarcoma. J Clin Oncol 1998; 16: 1697–706

    PubMed  CAS  Google Scholar 

  62. Bokemeyer C, Franzke A, Hartmann JT, et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997; 80: 1221–7

    Article  PubMed  CAS  Google Scholar 

  63. Samuels B, Elias A, Vogelzang N, et al. High dose chemotherapy with ABMT for refractory sarcoma [abstract]. Proc Am Soc Clin Oncol 1989; 8: 1068

    Google Scholar 

  64. Elias AD, Ayash LJ, Wheeler C, et al. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 1995; 15: 373–9

    PubMed  CAS  Google Scholar 

  65. Dumontet C, Biron P, Bouffet E, et al. High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases. Bone Marrow Transplant 1992; 10: 405–8

    PubMed  CAS  Google Scholar 

  66. Kessinger A, Petersen K, Bishop M, et al. High dose therapy with autologous hematopoietic stem cell rescue for patients with metastatic sarcoma [abstract]. Proc Am Soc Clin Oncol 1994; 13: 1674

    Google Scholar 

  67. Mesia R, Sola C, Lopez Pousa A, et al. High-dose chemotherapy and autologous bone marrow transplantation in high-grade metastatic sarcomas. Rev Clin Esp 1994; 194: 960–5

    PubMed  CAS  Google Scholar 

  68. Blay J-Y, Bouhour D, Ray-Coquard I, et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 2000; 18: 3643–50

    PubMed  CAS  Google Scholar 

  69. Rosti G, Philip T, Chauvin F, et al. European Group for Blood and Bone Marrow Transplantation (EBMT) registry in solid tumors: a 12 years experience [abstract]. Bone Marrow Transplant 1997; 17: 469

    Google Scholar 

  70. Blay JY, van Glabbeke M, Nielsen OS, et al. Five-year survivors in patients (pts) with advanced soft tissue sarcoma (ASTS) treated with doxorubicin: a study on 1742 patients (STBSG) [abstract]. Proc Am Soc Clin Oncol 1998; 17: 512a

    Google Scholar 

  71. Yap BS, Sincovics JG, Burgess MA, et al. The curability of advanced soft tissue sarcomas in adult with chemotherapy [abstract]. Proc Am Soc Clin Oncol 1983; 1: 239

    Google Scholar 

  72. Wiklund T, Saeter G, Strander H, et al. The outcome of advanced soft tissue sarcoma patients with complete tumor regression after either chemotherapy alone or chemotherapy plus surgery. Eur J Cancer 1997; 33(3): 357–61

    Article  PubMed  CAS  Google Scholar 

  73. Antman KH, Elias A. Dana-Farber Cancer Institute studies in advanced sarcoma. Semin Oncol 1990; 17Suppl. 2: 7–15

    PubMed  CAS  Google Scholar 

  74. Pastorino U. Metastasectomy for soft tissue sarcomas. In: Verweij J, Pinedo HM, Suit H, editors. Soft tissue sarcomas: present achievements and future prospects. Boston (MA): Kluwer Academic Publishers, 1997: 65–75

  75. Miller DS, Blessing JA, Kilgore LC, et al. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. Am J Clin Oncol 2000; 23(4): 355–7

    Article  PubMed  CAS  Google Scholar 

  76. Merimsky O, Meller I, Flusser G, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 2000; 45(2): 177–81

    Article  PubMed  CAS  Google Scholar 

  77. Blay JY, Judson I, Rodenhuis S, et al. Phase II study of raltitrexed (‘Tomudex’) for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Anticancer Drugs 1999; 10: 873–7

    Article  PubMed  CAS  Google Scholar 

  78. Woll PJ, Judson I, Lee SM, et al. Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1999; 35: 410–2

    Article  PubMed  CAS  Google Scholar 

  79. Kindblom L-G, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259–69

    PubMed  CAS  Google Scholar 

  80. Sircar K, Hewlett BR, Huizinga JD, et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23: 377–89

    Article  PubMed  CAS  Google Scholar 

  81. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577–80

    Article  PubMed  CAS  Google Scholar 

  82. VanGlabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcomas: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens: a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncology 1999; 17: 150–7

    Google Scholar 

  83. Platt BE, Hollema H. Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000; 18: 3211–20

    Google Scholar 

  84. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472–480

    Article  PubMed  CAS  Google Scholar 

  85. Van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 2001; 358: 1421–3

    Article  PubMed  Google Scholar 

  86. Van Glabbeke M, Verweij J, Judson I, et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38: 93–8

    Google Scholar 

  87. Billingsley KG, Lewis JJ, Leung DH, et al. Multifactorial analysis of the survival f patients with distant metastases arising from primary extremity sarcoma. Cancer 1999; 85(2): 389–95

    Article  PubMed  CAS  Google Scholar 

  88. van Geel AN, van Coevorden F, Blankensteijn JD, et al. Surgical treatment of pulmonary metastases from soft tissue sarcomas: a retrospective study in the Netherlands. J Surg Oncol 1994; 56: 172–7

    Article  PubMed  Google Scholar 

  89. Ueda T, Uchida A, Kodama K, et al. Aggressive pulmonary metastasectomy for soft tissue sarcomas. Cancer 1993; 72: 1919–25

    Article  PubMed  CAS  Google Scholar 

  90. Temeck BK, Wewter LH, Streinberg SM, et al. Metastasectomy for sarcomatous pediatric histologies: results and prognostic factors. Ann Thorac Surg 1995; 59(6): 1386–9

    Article  Google Scholar 

  91. Verazin GT, Warneke JA, Driscoll DL, et al. Resection of lung metastases from soft-tissue sarcomas: a multivariate analysis. Arch Surg 1992; 127: 1407–11

    Article  PubMed  CAS  Google Scholar 

  92. Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of disease and postmetastasis survival. Ann Surg 1999; 229(5): 610–2

    Article  Google Scholar 

  93. Choong PF, Pritchard DJ, Rock MG, et al. Survival after pulmonary metastasectomy in soft tissue sarcoma. Prognostic factors in 214 patients. Acta Orthop Scand 1995; 66(6): 561–8

    Article  PubMed  CAS  Google Scholar 

  94. Weiser MR, Downey RJ, Leung DH, et al. Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J Am Coll Surg 2000; 191(2): 184–90

    Article  PubMed  CAS  Google Scholar 

  95. VanGlabbeke M, Donate Di Paola E, Mouridsen H, et al. Response to anthracycline based chemotherapy (ABC) and overall survival in patients (PTS) with lung metastases from tissues sarcoma (STS): a retrospective study of the EORTC soft tissue and bone sarcoma group (STBSG) [abstract]. J Clin Oncol 1999; 18: 542a(2093)

    Google Scholar 

  96. Putnam JB, Roth JA. Surgical management for pulmonary metastases from sarcomas. Hematol Oncol Clin North Am 1995; 9: 869–86

    PubMed  Google Scholar 

Download references

Acknowledgements

The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Ole S. Nielsen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nielsen, O.S., Blay, JY., Judson, I.R. et al. Metastatic Soft Tissue Sarcoma in Adults. Am J Cancer 2, 211–221 (2003). https://doi.org/10.2165/00024669-200302030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024669-200302030-00005

Keywords

Navigation